Discrepancies were identified between two genetic analysis platforms used to detect mutations that guide the treatment of ovarian, fallopian tube, or primary peritoneal cancers in…
News
Abbvie is teaming up with China-based company Simcere Zaiming to advance the development of SIM0500, Simcere’s experimental treatment for multiple myeloma that’s…
PANCREATIC CANCER
Germany clears pelareorep pancreatic cancer trial continuation
Authorities in Germany have given Oncolytics Biotech the go-ahead to continue enrollment in a Phase 1/2 clinical trial testing the company’s viral therapy pelareorep…
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to a novel brain cancer treatment — one designed for malignant gliomas…
GYNECOLOGICAL CANCER
Medicaid expansion can raise demand for gynecologic cancer care
An expansion of Medicaid services in the state of Virginia led within months to more young and middle-aged women of lower income being treated in…
A subcutaneous, or under-the-skin, formulation of Sarclisa (isatuximab) is just as effective as the approved intravenous (into-the-vein) version of the therapy at controlling treatment-resistant…
The U.S. Food and Drug Administration (FDA) has granted fast track designation to Puretech Health’s LYT-200, an investigative treatment for acute myeloid leukemia…
PANCREATIC CANCER
MEK inhibitor IMM-1-104 shows promise in pancreatic cancer: Data
Investigational oral therapy IMM-1-104 was well tolerated and showed early signs of efficacy as a first- or second-line treatment for pancreatic cancer. That’s according…
Brainchild Bio plans to launch a pivotal Phase 2 clinical trial to test its investigational cell therapy BCB-276 in patients with diffuse intrinsic pontine…
GYNECOLOGICAL CANCER
FDA reviewing oral combination treatment for ovarian cancer
The U.S. Food and Drug Administration (FDA) has agreed to review Verastem Oncology’s application seeking approval of a combination of avutometinib and defactinib for…
Recent Posts
- The parallel calendars: Living between treatment cycles and ordinary days
- First participant receives GLIX1 in early glioblastoma clinical trial
- World Ovarian Cancer Day campaign spotlights scars seen and unseen
- Gilead completes Arcellx buy, securing myeloma treatment anito-cel
- Why the answer to ‘Should I call the doctor?’ is always yes
